Biohaven Q3 net loss narrows as expenses fall

Overview

• Biopharmaceutical firm's Q3 net loss narrowed yr/yr as expenses declined

• Lower R&D and G&A costs drove reduced loss, reflecting program reprioritization and lower employee expenses

• Company announced licensing deals with SK Biopharmaceuticals and Ono Pharmaceutical, bringing up to $500 mln in near-term cash

Outlook

• FDA decision on Vyglxia in SCA expected 1Q 2027

• Company plans to start BHV-1400 pivotal IgAN trial in 4Q 2026

• Topline data for opakalim Phase 2/3 epilepsy study expected in 2H 2026

Result Drivers

• PROGRAM REPRIORITIZATION - Co attributed lower R&D expenses to strategic reprioritization of programs, reducing direct and preclinical spend

• LOWER EMPLOYEE COSTS - Co said reduced G&A expenses were driven by lower employee costs, including share-based compensation

• LICENSING DEALS - Co secured up to $500 mln in near-term cash from SK Biopharmaceuticals and Ono Pharmaceutical licensing agreements

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Biohaven Ltd. is $24.00, about 54.6% above its October 28 closing price of $15.52

Reuters Recommended Reads

• Oct 29 - Kymera Q3 net loss widens as R&D costs rise

• Oct 29 - UK's Bicycle Therapeutics Q3 loss narrows as expenses fall

• Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)